Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
CARA on Nasdaq
Shares outstanding
54,790,889
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Vifor (International) Ltd 14% $2,458,686 7,396,770 Vifor (International) Ltd. 17 Dec 2024

Institutional Holders of Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q1 0 $0 -$7,158 0
2024 Q4 20,164 $7,158 -$3,973,383 $0.36 1
2024 Q3 13,514,237 $4,159,096 -$1,032,751 $0.31 65
2024 Q2 17,684,088 $4,561,540 -$4,042,593 $0.26 76
2024 Q1 23,514,485 $21,396,518 -$426,875 $0.91 96
2023 Q4 24,377,112 $18,109,185 -$5,083,037 $0.74 107
2023 Q3 27,123,062 $45,563,127 -$6,587,024 $1.68 121
2023 Q2 29,289,778 $82,888,748 -$18,896,002 $2.83 131
2023 Q1 33,889,306 $166,391,687 -$5,477,111 $4.91 161
2022 Q4 33,996,854 $365,121,945 -$4,541,381 $10.74 161
2022 Q3 34,612,850 $323,992,355 -$2,083,804 $9.36 152
2022 Q2 34,812,812 $317,864,785 +$23,430,633 $9.13 166
2022 Q1 31,735,791 $385,591,868 +$16,589,053 $12.15 177
2021 Q4 30,295,793 $368,853,803 +$3,325,166 $12.18 174
2021 Q3 29,597,983 $457,112,862 +$1,903,784 $15.45 161
2021 Q2 29,619,793 $422,555,895 -$29,484,537 $14.27 162
2021 Q1 29,844,915 $647,894,469 +$3,235,940 $21.71 156
2020 Q4 29,864,210 $451,866,505 -$10,514,992 $15.13 146
2020 Q3 30,605,125 $389,630,505 +$7,883,789 $12.72 152
2020 Q2 29,920,527 $511,617,407 +$22,432,806 $17.10 136
2020 Q1 32,217,643 $425,460,027 +$9,271,004 $13.21 130
2019 Q4 31,365,475 $505,318,090 +$4,578,062 $16.11 146
2019 Q3 30,528,396 $558,121,704 +$81,405,292 $18.28 140
2019 Q2 26,022,034 $559,418,629 +$84,321,964 $21.50 122
2019 Q1 22,307,202 $437,676,305 -$26,628,851 $19.62 130
2018 Q4 24,252,310 $315,074,723 -$3,522,463 $13.00 129
2018 Q3 23,452,027 $561,612,752 +$111,415,387 $23.95 141
2018 Q2 18,764,234 $359,338,384 +$24,241,175 $19.15 122
2018 Q1 17,934,850 $221,836,124 +$8,896,641 $12.38 116
2017 Q4 13,668,528 $167,392,966 -$24,154,898 $12.24 122
2017 Q3 15,548,215 $212,721,305 -$11,553,188 $13.69 116
2017 Q2 19,921,450 $306,627,408 +$37,073,627 $15.39 125
2017 Q1 17,021,870 $312,676,249 +$101,013,666 $18.39 109
2016 Q4 13,764,777 $127,888,593 +$13,025,567 $9.29 98
2016 Q3 11,609,560 $96,937,885 +$6,055,428 $8.35 78
2016 Q2 11,908,919 $57,274,967 -$25,677,121 $4.81 63
2016 Q1 16,228,642 $100,929,732 -$43,522,582 $6.22 91
2015 Q4 19,629,819 $330,876,371 +$18,693,953 $16.86 93
2015 Q3 18,553,564 $265,128,131 +$93,669,119 $14.29 88
2015 Q2 12,065,581 $146,597,682 +$14,135,862 $12.15 74
2015 Q1 11,149,349 $112,187,948 +$13,425,176 $10.05 59
2014 Q4 9,218,398 $92,056,301 -$3,867,664 $9.97 54
2014 Q3 9,715,313 $81,499,006 +$5,569,556 $8.39 53
2014 Q2 8,774,155 $149,338,478 +$751,547 $17.02 47
2014 Q1 8,621,122 $160,437,942 +$160,207,942 $18.61 42